Product Name: Frk (19-35)
Product Number: PE-01BCX90
| Size: | 200 µg | Price: | 50.00 | |
| 1 mg | $US | 101.00 | ||
| 5 mg | 238.00 |
Peptide Name: Frk (19-35)
Product Use: Services as a blocking peptide for use with the Frk-ANT rabbit polyclonal antibody (Cat. No.: AB-NK269-1) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LSTEADKSTVIENPGALC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1847 Da
Peptide Purity Percent after Synthesis and Purification: >90
Product Use: Services as a blocking peptide for use with the Frk-ANT rabbit polyclonal antibody (Cat. No.: AB-NK269-1) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LSTEADKSTVIENPGALC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1847 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Frk pan-specific antibody (Cat. No.: AB-NK269-1)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Frk pan-specific antibody (Cat. No.: AB-NK269-1)
Scientific Background: Frk is a protein-tyrosine kinase of the TK group and Src family that is found in the nucleus.. It is involved in positive regulation of PTEN by increasing its stability and preventing degradation and negative regulation of cell proliferation. It may also have functions during G1 and S phase in the nucleus to suppress growth. Frk may be a tumour suppressor protein (TSP). Cancer-related mutations in human tumours point to a loss of function of the protein kinase. nsertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.
© Kinexus Bioinformatics Corporation 2017